Inventor
URECH DAVID
CH45 patents
⚠️ This page may combine multiple inventors who share the name “URECH DAVID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ESBATECH ALCON BIOMED RES UNIT
16 patentsUS9090684B2Jul 28, 2015
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT54 citations97
US9422366B2Aug 23, 2016
Stable and soluble antibodies inhibiting TNF alpha
ESBATECH ALCON BIOMED RES UNIT12 citations92
US8349322B2Jan 8, 2013
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT31 citations92
US10590193B2Mar 17, 2020
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT9 citations83
US10100111B2Oct 16, 2018
Stable and soluble antibodies inhibiting TNF alpha
ESBATECH ALCON BIOMED RES UNIT7 citations83
US9873737B2Jan 23, 2018
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT10 citations83
US10087244B2Oct 2, 2018
Humanization of rabbit antibodies using a universal antibody framework
ESBATECH ALCON BIOMED RES UNIT6 citations82
US9593161B2Mar 14, 2017
Humanization of rabbit antibodies using a universal antibody framework
ESBATECH ALCON BIOMED RES UNIT7 citations82
US9683034B2Jun 20, 2017
Stable and soluble antibodies inhibiting TNFα
ESBATECH ALCON BIOMED RES UNIT2 citations72
US9803027B2Oct 31, 2017
Method for decreasing immunogenicity
ESBATECH ALCON BIOMED RES UNIT2 citations71
US9598487B2Mar 21, 2017
Stable and soluble antibodies
ESBATECH ALCON BIOMED RES UNIT2 citations71
US9908940B2Mar 6, 2018
Humanized immunobinders of cell-surface antigens
ESBATECH ALCON BIOMED RES UNIT1 citations60
US9221905B2Dec 29, 2015
Methods for producing immunobinders of cell-surface antigens
ESBATECH ALCON BIOMED RES UNIT2 citations60
US10221237B2Mar 5, 2019
Solubility optimization of immunobinders
ESBATECH ALCON BIOMED RES UNIT0 citations52
US9371525B2Jun 21, 2016
Functionalized polypeptides
ESBATECH ALCON BIOMED RES UNIT0 citations52
US8691228B2Apr 8, 2014
Stable and soluble antibodies inhibiting TNFα
ESBATECH ALCON BIOMED RES UNIT0 citations51
Numab Therapeutics AG
8 patentsUS11879005B2Jan 23, 2024
Hetero-dimeric multi-specific antibody format
Numab Therapeutics AG0 citations62
US11427628B2Aug 30, 2022
Antibody frameworks
Numab Therapeutics AG0 citations62
US11236150B2Feb 1, 2022
Hetero-dimeric multi-specific antibody format
Numab Therapeutics AG1 citations62
US11319371B2May 3, 2022
Anti-CD3 antibodies
Numab Therapeutics AG1 citations57
US12202911B2Jan 21, 2025
Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
Numab Therapeutics AG0 citations56
US12503505B2Dec 23, 2025
Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereof
Numab Therapeutics AG0 citations50
US12098203B2Sep 24, 2024
Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
Numab Therapeutics AG0 citations49
US11421035B2Aug 23, 2022
Stable antibody variable domain framework combinations and methods of use thereof
Numab Therapeutics AG0 citations45
URECH DAVID
5 patentsUS8227199B2Jul 24, 2012
Methods for identifying immunobinders of cell-surface antigens
URECH DAVID10 citations81
US8796425B2Aug 5, 2014
Method for decreasing immunogenicity
URECH DAVID3 citations60
US8465937B2Jun 18, 2013
Methods for identifying B-clones which bind cell-surface antigens
URECH DAVID2 citations60
US8637022B2Jan 28, 2014
Functionalized polypeptides
URECH DAVID0 citations51
US9908945B2Mar 6, 2018
Sequence based engineering and optimization of single chain antibodies
URECH DAVID0 citations40
NOVARTIS AG
5 patentsUS10570198B2Feb 25, 2020
Stable and soluble antibodies
NOVARTIS AG3 citations71
US11858981B2Jan 2, 2024
Humanization of rabbit antibodies using a universal antibody framework
NOVARTIS AG0 citations62
US11578123B2Feb 14, 2023
Stable and soluble antibodies inhibiting TNFα
NOVARTIS AG0 citations62
US11046757B2Jun 29, 2021
Solubility optimization of immunobinders
NOVARTIS AG0 citations62
US10781268B2Sep 22, 2020
Method for decreasing immunogenicity
NOVARTIS AG0 citations52
BORRAS LEONARDO
4 patentsUS8673310B2Mar 18, 2014
Stable and soluble antibodies inhibiting TNFα
BORRAS LEONARDO36 citations97
US8293235B2Oct 23, 2012
Humanization of rabbit antibodies using a universal antibody framework
BORRAS LEONARDO49 citations97
US8937162B2Jan 20, 2015
Humanization of rabbit antibodies using a universal antibody framework
BORRAS LEONARDO14 citations92
US9556265B2Jan 31, 2017
Solubility optimization of immunobinders
BORRAS LEONARDO3 citations72
ROCKWELL AUTOMATION SWITZERLAND GMBH
3 patentsUS11437202B2Sep 6, 2022
Switching device with lock open component
ROCKWELL AUTOMATION SWITZERLAND GMBH0 citations59
US11862412B1Jan 2, 2024
System and method for reduced torque switching
ROCKWELL AUTOMATION SWITZERLAND GMBH0 citations41
US12387883B2Aug 12, 2025
System and method of detecting a welded contact
ROCKWELL AUTOMATION SWITZERLAND GMBH0 citations40